166 related articles for article (PubMed ID: 17024822)
1. [Changes of urinary enzyme activity in cancer of the urinary bladder].
Nizamova RS
Vopr Onkol; 2006; 52(4):455-7. PubMed ID: 17024822
[TBL] [Abstract][Full Text] [Related]
2. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Matsumoto K; Casella R; Jian W; Lerner SP
Eur Urol; 2005 Jul; 48(1):69-76. PubMed ID: 15967254
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer.
Pham HT; Block NL; Lokeshwar VB
Cancer Res; 1997 Feb; 57(4):778-83. PubMed ID: 9044860
[TBL] [Abstract][Full Text] [Related]
4. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer.
Tzai TS; Tsai YS; Shiau AL; Wu CL; Shieh GS; Tsai HT
Urology; 2006 Feb; 67(2):294-9. PubMed ID: 16461079
[TBL] [Abstract][Full Text] [Related]
5. Cellular fibronectin in patients with transitional cell carcinoma of the bladder.
Hegele A; Heidenreich A; Varga Z; von Knobloch R; Olbert P; Kropf J; Hofmann R
Urol Res; 2003 Feb; 30(6):363-6. PubMed ID: 12599015
[TBL] [Abstract][Full Text] [Related]
6. Limitations in the use of glutathione S-transferase P1 in urine as a marker for bladder cancer.
Lafuente A; Rodriguez A; Gibanel R; Lafuente MJ; Alonso M; Molina R; Ballesta A; Carretero P
Anticancer Res; 1998; 18(5B):3771-2. PubMed ID: 9854493
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of bladder cancer by analysis of urinary fibronectin.
Menéndez V; Fernández-Suárez A; Galán JA; Pérez M; García-López F
Urology; 2005 Feb; 65(2):284-9. PubMed ID: 15708039
[TBL] [Abstract][Full Text] [Related]
9. Considerations on the use of urine markers for bladder cancer.
van Rhijn BW
Eur Urol; 2008 May; 53(5):880-1. PubMed ID: 18222604
[No Abstract] [Full Text] [Related]
10. Studies on lactic dehydrogenase of patients with urinary bladder tumors. I. Urinary lactic dehydrogenase.
Motomiya Y; Ohzono S; Shiomi T; Kondo T; Ijuin M; Okajima E
Invest Urol; 1979 Sep; 17(2):120-4. PubMed ID: 468510
[TBL] [Abstract][Full Text] [Related]
11. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
Jamshidian H; Kor K; Djalali M
Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
[TBL] [Abstract][Full Text] [Related]
12. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
Bian W; Xu Z
Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
[TBL] [Abstract][Full Text] [Related]
13. Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma.
Margulies IM; Höyhtyä M; Evans C; Stracke ML; Liotta LA; Stetler-Stevenson WG
Cancer Epidemiol Biomarkers Prev; 1992; 1(6):467-74. PubMed ID: 1302559
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis.
Vasala K; Pääkko P; Turpeenniemi-Hujanen T
Anticancer Res; 2008; 28(3B):1757-61. PubMed ID: 18630455
[TBL] [Abstract][Full Text] [Related]
16. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
[TBL] [Abstract][Full Text] [Related]
18. Staining of bladder tumor cell dehydrogenase.
Kawamura N
Tokai J Exp Clin Med; 1980 Oct; 5(4):421-33. PubMed ID: 6166091
[TBL] [Abstract][Full Text] [Related]
19. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205
[TBL] [Abstract][Full Text] [Related]
20. Survivin mRNA expression in urine as a biomarker for patients with transitional cell carcinoma of bladder.
Hou JQ; He J; Wen DG; Chen ZX; Zeng J
Chin Med J (Engl); 2006 Jul; 119(13):1118-20. PubMed ID: 16834932
[No Abstract] [Full Text] [Related]
[Next] [New Search]
